Two extracts can both proudly declare “40% Mitragynine” on their Certificates of Analysis (COA). On paper, they appear identical. But in the manufacturing suite, one formulation succeeds while the other fails or worse, must be scrapped entirely. The culprit is rarely total alkaloid content; it is the unmeasured, invisible alkaloid “noise” caused by diastereomers like speciogynine, paynantheine and speciociliatine. For procurement managers and brand owners, understanding this hidden variable is the difference between supply chain reliability and chronic batch rejection.

The Financial Risk of Batch Rejection Due to Inconsistent Alkaloid “Noise”

Kratom leaves contain a complex mixture of indole alkaloids, including mitragynine, mitraciliatine, speciogynine and speciociliatine—all with the same molecular formula and connectivity, but different spatial arrangements that make them diastereomers.1 Traditional HPLC testing that reports only a single “mitragynine” value treats these distinct molecules as a single peak, completely masking substantial variation between batches.

This natural variation can lead to differences in potency between batches, making serving sizes less predictable and causing product performance to drift without warning.2 For a brand owner, the result is a cascade of financial pain: inconsistent finished products, failed stability studies, consumer complaints and, ultimately, rejected batches. In an era where manufacturers face material risk from private plaintiff litigation, product-liability claims and FDA enforcement across the supply chain, an inconsistent product is an invitation to regulatory scrutiny and legal exposure.

The global kratom extract market is projected to grow from USD 321 million in 2025 to nearly USD 700 million by 2035.3 In a maturing market, batch rejection is no longer a tolerable cost of doing business. It is a competitive disadvantage that erodes margins and destroys buyer confidence.

Beyond “40%”—Why Standard HPLC Testing Is Not Enough

Standard HPLC methods often lack the resolution to separate mitragynine from its diastereomers. Gas chromatography (GC) is even less satisfactory: it struggles to resolve mitragynine and speciociliatine because these diastereoisomers differ only in the orientation of a single hydrogen atom.4 If your laboratory method cannot distinguish these molecules, your COA is effectively reporting a sum rather than a true composition.

Modern analytical science, however, has moved beyond this limitation. An improved LC method reported in 2022 successfully achieved separation and individual measurement of the four diastereomers—mitragynine, mitraciliatine, speciogynine and speciociliatine—using a high-temperature silica-based column. High-resolution mass spectrometry (HRMS) can simultaneously quantify mitragynine, speciociliatine, speciogynine and paynantheine, providing a true full-alkaloid matrix rather than a single-number approximation.2

The takeaway is clear; if your supplier cannot perform diastereomer discrimination, they are not providing a complete picture of their extract. And in the absence of that picture, batch consistency is a gamble, not a guarantee.

How to Request Diastereomer Profiling in Your RFQ

Procurement managers can take immediate, practical action by incorporating diastereomer profiling into their Request for Quotation (RFQ). A well-crafted specification should move beyond a simple “Mitragynine ≥ X%” statement and require a full alkaloid matrix, including individual quantification of:

• Mitragynine

• Speciogynine

• Speciociliatine

• Mitraciliatine

• Paynantheine

The RFQ should also mandate that the supplier provide a COA from an independent laboratory using a validated LC–HRMS or LC–MS/MS method capable of diastereomer separation, referencing the improved LC method reported in the analytical literature. In parallel, requiring clear traceability—documenting the ingredient’s journey from raw material to finished product—adds an additional layer of accountability and helps verify that batch-to-batch variation is being actively managed rather than passively accepted.5

Including these requirements is not an unreasonable burden on suppliers; it is a quality gate that separates serious, science-driven manufacturers from those still operating with outdated, single-peak testing.

Diastereomer Discrimination as a Supply Chain Standard

The industry is moving toward higher quality standards. Several states have enacted or are considering Kratom Consumer Protection Acts, which impose labeling, registration and purity requirements. The American Herbal Products Association (AHPA) has adopted guidance clarifying the distinction between natural kratom and synthetic alkaloids, reinforcing the need for transparent, validated analytical methods.7 Meanwhile, voluntary recalls for contamination issues (including a 2024 FDA mandatory recall affecting multiple brands) have heightened scrutiny across the entire supply chain.6

In this environment, diastereomer discrimination is not just a technical nicety. It is a risk management tool. When every batch includes a quantified report of speciogynine, paynantheine and other key diastereomers, the buyer gains the ability to track consistency across shipments, set acceptance criteria in quality agreements and hold suppliers accountable for more than a single, easily gamed “40%” number.

Call to Action: Demand a Full Alkaloid Matrix COA Before Signing Your Purchase Order

The next time you receive a COA claiming “40% Mitragynine,” ask a simple question: Does this report show my speciogynine, paynantheine, and speciociliatine levels? If the answer is no, you are purchasing blind.

Make diastereomer profiling a non-negotiable item in your supplier qualification process. Require a full alkaloid matrix COA from an independent laboratory using validated LC–HRMS or LC–MS/MS diastereomer separation methods before signing your purchase order. Protect your formulations, your margins and your brand reputation from the hidden cost of “dirty” extract.

Reference:

1. Hassan Z, Muzaimi M, Navaratnam V, Yusoff NHM, Suhaimi FW, Vadivelu R, Vicknasingam BK, Amato D, von Hörsten S, Ismail NIW, Jayabalan N, Hazim AI, Mansor SM, Müller CP. (2013). From Kratom to Mitragynine and Its Derivatives: Physiological and Behavioural Effects Related to Use, Abuse, and Addiction. Neuroscience & Biobehavioral Reviews, 37(2):138–151. doi: https://doi.org/10.1016/j.neubiorev.2012.11.012

2. Philipp AA, Wissenbach DK, Weber AA, Zapp J, Maurer HH. (2011). Metabolism Studies of the Kratom Alkaloids Mitraciliatine and Isopaynantheine, Diastereomers of the Main Alkaloids Mitragynine and Paynantheine, in Rat and Human Urine Using Liquid Chromatography–Linear Ion Trap–Mass Spectrometry. Journal of Chromatography B, 879(15–16):1049–1055. doi: https://doi.org/10.1016/j.jchromb.2011.03.039

3. StatiFacts. (2025). Kratom Extract Market Size, Share, and Forecast. Retrieved May 27, 2026, from https://www.statifacts.com/outlook/kratom-extract-market

4. Corkery JM, Streete P, Claridge H, Goodair C, Papanti D, Orsolini L, Schifano F, Sikka K, Körber S, Hendricks A. (2022). Characteristics of Deaths Associated With Kratom Use. Journal of Psychopharmacology, 36(1):110–123. doi: https://doi.org/10.1177/02698811211036338

5. Mayer Brown. (2026). The Emerging Kratom Litigation Landscape and Implications for Similarly Situated Manufacturers. Retrieved May 27, 2026, from https://www.mayerbrown.com/fr/insights/publications/2026/05/the-emerging-kratom-litigation-landscape-and-implications-for-similarly-situated-manufacturers

6. SupplySide SJ. (2026). FDA Seizes $1 Million Worth of 7-OH Products. Retrieved May 27, 2026, from https://www.supplysidesj.com/supplement-regulations/fda-seizes-1-million-worth-of-7-oh

7. Industry Today. (2025). Kratom Compliance in an Evolving Regulatory Landscape. Retrieved May 27, 2026, from https://industrytoday.com/kratom-compliance-in-an-evolving-regulatory-landscape/